Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189312 | 1.00 | KMT2A (0.42) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL3189307 | 1.00 | KMT2A (0.42) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL20183392 | 1.00 | KMT2A (0.42) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL769859 | 0.84 | KMT2A (0.41) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL785824 | 0.84 | KMT2A (0.41) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL769861 | 0.84 | KMT2A (0.41) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL769860 | 0.84 | KMT2A (0.41) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL13484126 | 0.82 | HSD11B1 (0.39) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL3203744 | 0.82 | HSD11B1 (0.39) | KMT2AHSD11B1MAPK1METAP2CYP2D6 | |
| SCHEMBL3195911 | 0.82 | HSD11B1 (0.39) | KMT2AHSD11B1MAPK1METAP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | KMT2A 1054/4885HSD11B1 988/4885MAPK1 13/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | KMT2A 2046/4885HSD11B1 2049/4885MAPK1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.